Association between hyperandrogenism and adverse pregnancy outcomes in patients with different polycystic ovary syndrome phenotypes undergoing in vitro fertilization/intracytoplasmic sperm injection: a systematic review and meta-analysis

References

• Escobar-Morreale Héctor F. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–284.
   PubMed Web of Science ®Google Scholar
• Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2003;81:19–25.
   Web of Science ®Google Scholar
• Bozdag G, Mumusoglu S, Zengin D, et al. The prevalence and phenotypic features of polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2016;31(12):2841–2855.
   PubMed Web of Science ®Google Scholar
• Li R, Zhang Q, Yang D, et al. Prevalence of polycystics ovary syndrome in women in China: a large community-based study. Hum Reprod. 2013;28(9):2562–2569.
   PubMed Web of Science ®Google Scholar
• Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2013;98(12):4565–4592.
   PubMed Web of Science ®Google Scholar
• Jayasena CN, Franks S. The management of patients with polycystic ovary syndrome. Nat Rev Endocrinol. 2014;10(10):624–636.
   PubMed Web of Science ®Google Scholar
• Kavardzhikova S, Pechlivanov B. Clinical, hormonal and metabolic characteristics of different phenotypes of polycystic ovary syndrome, in Bulgarian population. Akush Ginekol. 2010;49(4):32–37.
   PubMedGoogle Scholar
• Gaddas M, Chaouache N, Ajina M, et al. Does hyperandrogenic statute in the polycystic ovary syndrome constitute an obstacle to the success of in vitro fertilization? J Gynecol Obstet Biol Reprod. 2016;45(9):1091–1098.
   PubMedGoogle Scholar
• Cela V, Obino MER, Alberga Y, et al. Ovarian response to controlled ovarian stimulation in women with different polycystic ovary syndrome phenotypes. Gynecol Endocrinol. 2018;34(6):518–523.
   PubMed Web of Science ®Google Scholar
• Ramezanali F, Ashrafi M, Hemat M, et al. Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes: the predictive value of anti-Müllerian hormone. Reprod Biomed Online. 2016;32(5):503–512.
   PubMed Web of Science ®Google Scholar
• Hinneburg I. ROBINS-1: a tool for asssessing risk of bias in non-randomised studies of interventions. Med Monatsschr Pharm. 2017;40(4):175–177.
   PubMedGoogle Scholar
• Eftekhar M, Mirhashemi ES, Tabibnejad N. Assisted reproductive outcomes in women with different polycystic ovary syndrome phenotypes. Int J Gynecol Obstet. 2019;144(2):147–152.
   PubMed Web of Science ®Google Scholar
• Li M, Song J, Chen SL, et al. Association of the clinical characteristics and the IVF-ET outcome in infertile women with polycystic ovarian syndrome of different subtypes. Nan Fang Yi Ke Da Xue Xue Bao. 2009;29:224–227.
   PubMedGoogle Scholar
• De Vos M, Pareyn S, Drakopoulos P, et al. Cumulative live birth rates after IVF in patients with polycystic ovaries: phenotype matters. Reprod Biomed Online. 2018;37(2):163–171.
   PubMed Web of Science ®Google Scholar
• Yang W, Yang R, Yang S, et al. Infertile polycystic ovary syndrome patients undergoing in vitro fertilization with the gonadotropin-releasing hormone-antagonist protocol: role of hyperandrogenism. Gynecol Endocrinol. 2018;34(8):715–718.
   PubMed Web of Science ®Google Scholar
• Eldar-Geva T, Margalioth EJ, Gal M, et al. Serum anti-Mullerian hormone levels during controlled ovarian hyperstimulation in women with polycystic ovaries with and without hyperandrogenism. Hum Reprod. 2005;20(7):1814–1819.
   PubMed Web of Science ®Google Scholar
• Wu M, Xiao G, Yang J, et al. J. Effect of IVF-ET outcome on different types of PCOS patients treated with GnRH agonist long protocol. Guangdong Med J. 2018;39(01):103–106.
   Google Scholar
• Luo L, Liu J, Li J, et al. Analysis of different subtypes of polycystic ovary syndrome and pregnancy outcome after in-vitro fertilization and embryo transfer. J Prac Obste Gynecol. 2010;26(10):787–790.
   Google Scholar
• Selçuk S, Özkaya E, Eser A, et al. Characteristics and outcomes of in vitro fertilization in different phenotypes of polycystic ovary syndrome. Turk J Obstet Gynecol. 2016;13(1):1–6.
   PubMed Web of Science ®Google Scholar
• Yilmaz M, Isaoglu U, Delibas IB, et al. Anthropometric, clinical and laboratory comparison of four phenotypes of polycystic ovary syndrome based on Rotterdam criteria. J Obstet Gynaecol Res. 2011;37(8):1020–1026.
   PubMed Web of Science ®Google Scholar
• Batcheller AE, Rodriguez-Peterson KA, Martinez AM, et al. Hyperandrogenic Polycystic Ovary Syndrome (PCOS) patients have reduced pregnancy rates compared to non-hyperandrogenic PCOS patients following in vitro fertilization (IVF). Reproductive Sciences. 2013;20(3):177A–178A.
   Google Scholar
• Banu J, Fatima P, Sultana P, et al. Association of infertile patients having polycystic ovarian syndrome with recurrent miscarriage. Mymensingh Med J. 2014;23(4):770–773.
   PubMedGoogle Scholar
• Cocksedge KA, Saravelos SH, Metwally M, et al. How common is polycystic ovary syndrome in recurrent miscarriage? Reprod Biomed Online. 2009;19(4):572–576.
   PubMed Web of Science ®Google Scholar
• Cocksedge KA, Saravelos SH, Wang Q, et al. Does free androgen index predict subsequent pregnancy outcome in women with recurrent miscarriage? Hum Reprod. 2008;23(4):797–802.
   PubMed Web of Science ®Google Scholar
• Palomba S, Piltonen TT, Giudice LC. Endometrial function in women with polycystic ovary syndrome: a comprehensive review. Hum Reprod Update. 2020;
   PubMed Web of Science ®Google Scholar
• Rosas C, Oróstica L, Poblete C, et al. Hyperandrogenism decreases GRP78 protein level and glucose uptake in human endometrial stromal cells. Reprod Sci. 2016;23(6):761–770.
   PubMed Web of Science ®Google Scholar
• Lam P, Johnson I, Raine-Fenning N. Endometrial blood flow is impaired in women with polycystic ovarian syndrome who are clinically hyperandrogenic. Ultrasound Obstet Gynecol. 2009;34(3):326–334.
   PubMed Web of Science ®Google Scholar
• Palomba S, Daolio J, La Sala GB. Oocyte competence in women with polycystic ovary syndrome. Trends Endocrinol Metab. 2017;28(3):186–198.
   PubMed Web of Science ®Google Scholar
• Foroozanfard F, Asemi Z, Bazarganipour F, et al. Comparing pregnancy, childbirth, and neonatal outcomes in women with different phenotypes of polycystic ovary syndrome and healthy women: a prospective cohort study. Gynecol Endocrinol. 2020;36(1):61–65.
   PubMed Web of Science ®Google Scholar
• Palomba S, de Wilde Marlieke A, Angela F, et al. Pregnancy complications in women with polycystic ovary syndrome. Hum Reprod Update. 2015;21(5):575–592.
   PubMed Web of Science ®Google Scholar